Human TRAILR4/TNFRSF10D Antibody Summary
Ala56-His211
Accession # Q9UBN6
Applications
Human TRAIL R4/TNFRSF10D Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.
View Larger
Detection of Human TRAILR4/TNFRSF10D/DcR2 by Flow Cytometry Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells(A) Expression levels of EGFR, HER2, HER3, EpCAM, and TRAIL-receptors were investigated after treatment of the cells with medium or 250 ng/ml BZB for 16 h. (B) Serial dilutions of the molecules were analyzed. (C) 20 nM scTRAIL units were analyzed after preincubation of the cells with PBA or a 200-fold molar excess of the respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were detected via anti-FLAG-PE. relative MFI, relative median fluorescence intensity. Pairwise comparisons were performed by unpaired t test (two-tailed; *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05). Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.24379), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAILR4/TNFRSF10D
Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
- Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
- Pan, G. et al. (1998) FEBS lett 424:41.
- Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
- Degli-Esposti, M.A. et al. (1997) Immunity 7:813.
Product Datasheets
Citations for Human TRAILR4/TNFRSF10D Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
18
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization
Authors: Yoshihiro Suzuki-Karasaki, Kyoko Fujiwara, Kosuke Saito, Miki Suzuki-Karasaki, Toyoko Ochiai, Masayoshi Soma
Oncotarget
-
Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
Authors: L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak
PLoS ONE, 2018-06-21;13(6):e0198203.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
J Biol Chem, 2014-04-24;289(23):16576-87.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
Anticancer Res, 2014-02-01;34(2):729-34.
Species: Rat
Sample Types: Whole Cells
Applications: Flow Cytometry -
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Cancer Gene Ther., 2012-07-06;19(9):652-8.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
J. Cell. Physiol., 2010-02-01;222(2):357-64.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
Blood, 2009-08-18;114(18):3854-63.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
Stem Cells, 2008-09-04;26(11):2955-63.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
Mol. Cancer Ther., 2008-08-01;7(8):2328-38.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
J. Cell. Biochem., 2008-05-15;104(2):595-605.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
Oncogene, 2008-03-17;27(30):4161-71.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
Cell Death Differ., 2008-01-18;15(4):718-729.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
J. Invest. Dermatol., 2007-05-10;127(10):2425-37.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Authors: Singh TR, Shankar S, Srivastava RK
Oncogene, 2005-07-07;24(29):4609-23.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
Authors: Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm et al.
Molecules
-
Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
Authors: JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim
Sci Rep, 2020-11-17;10(1):19997.
-
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
Authors: Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al.
Cancers (Basel)
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRAILR4/TNFRSF10D Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human TRAILR4/TNFRSF10D Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
SW480 cells were treated with 5-FU (1 mg/ml) for indicated time points. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R4 Antibody (MAB633). A specific band was detected for TRAIL R4 at approximately 45-55 kDa. This experiment was conducted under reducing conditions.
